For patients and families facing an ocular melanoma diagnosis, one of the greatest concerns is often the treatment itself. Surgery, recovery time, potential vision changes, and the emotional impact of a cancer diagnosis can feel overwhelming. New developments from Louisiana, however, may offer hope for a simpler and less invasive approach for certain patients with eye cancer.
Dr. Paul Finger, a nationally recognized ocular oncologist and Director of Ocular Oncology at Tulane School of Medicine, has developed a new radiation treatment device called the iWand®, which may allow some eye tumors to be treated without surgery.
The treatment recently gained attention after being used to successfully treat a patient diagnosed with iris melanoma, a rare form of ocular melanoma that develops in the colored part of the eye.
Traditionally, many eye melanomas are treated using plaque brachytherapy, a highly effective procedure in which a small radioactive plaque is surgically attached to the eye near the tumor. While this approach has helped save both vision and eyes for thousands of patients, it typically requires surgery to place and later remove the plaque.
The newly developed iWand takes a different approach.
For tumors located toward the front of the eye, such as some iris melanomas, the handheld device delivers a carefully calculated dose of radiation directly to the tumor in approximately 10 to 15 minutes. In select cases, no surgical incision is required. Instead, the device is gently positioned over the affected area while the eye is numbed with drops and the patient receives light sedation.
According to Dr. Finger, the radiation dose is designed to provide a treatment effect comparable to traditional plaque therapy while dramatically reducing treatment time and recovery demands.
The potential benefits are significant. Patients may avoid surgery, reduce time away from work and family, and experience little to no downtime following treatment. The procedure is also covered by insurance and is currently available at only a handful of centers in the United States.
It is important to note that this treatment is not intended for every ocular melanoma patient. Tumor size, location, and individual circumstances all influence treatment decisions. However, the development of the iWand represents another important step toward more personalized and patient-friendly care.
The story also highlights the importance of regular eye examinations. In this case, the patient’s melanoma was discovered during a routine eye evaluation following cataract surgery. Early detection remains one of the most important factors in preserving vision and achieving successful treatment outcomes.
For the ocular melanoma community, innovations like the iWand demonstrate that progress continues to move beyond simply treating cancer toward improving the overall patient experience. As researchers and clinicians develop less invasive approaches, patients may one day have more options than ever before when facing an eye cancer diagnosis.